Ibrahim Vanessa, Isroff Catherine, Stephen Christopher D, Iyer Jay, Dale Marian L, Gunzler Douglas A, Bayram Ece, Xie Tao, Pantelyat Alex, Montaser-Kouhsari Leila, Garcia-Cordero Indira, Tartaglia Maria Carmela, Lang Anthony E, Swan Matthew, Boxer Adam L, Golbe Lawrence I, Wills Anne-Marie
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Departments of Molecular and Cellular Biology and Statistics, Harvard University, Cambridge, MA, United States.
Front Neurol. 2024 Dec 4;15:1501206. doi: 10.3389/fneur.2024.1501206. eCollection 2024.
The Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed.
To evaluate the MoCA as an outcome measure in PSP clinical trials.
Cognitive data from 162 participants in the placebo arm of the Biogen PASSPORT study (NCT03068468) were analyzed using linear mixed-effects modeling (LMM) and repeated measures correlation.
There was a significant decline in the MoCA score over time of -1.4 (95% CI -0.84 to -1.97) points over a 48-week period ( < 0.0001). Small but significant changes ( < 0.01) were observed in all MoCA domains except abstraction. The MoCA correlated weakly with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) over time ( = 0.1, = 0.02) but exhibited a stronger correlation with the PSP Rating Scale (PSPRS) ( = -0.25, < 0.0001).
The MoCA appears to have limited sensitivity in capturing cognitive decline in PSP.
蒙特利尔认知评估量表（MoCA）是一种经过充分验证的全面认知筛查工具。其在进行性核上性麻痹（PSP）中的有效性尚未得到评估。
评估MoCA作为PSP临床试验中的一项结局指标。
使用线性混合效应模型（LMM）和重复测量相关性分析了来自Biogen PASSPORT研究（NCT03068468）安慰剂组162名参与者的认知数据。
在48周期间，MoCA评分随时间显著下降，下降幅度为-1.4（95%置信区间-0.84至-1.97）分（P<0.0001）。除抽象能力外，在所有MoCA领域均观察到微小但显著的变化（P<0.01）。随着时间的推移，MoCA与可重复神经心理状态评估量表（RBANS）的相关性较弱（r = 0.1，P = 0.02），但与PSP评定量表（PSPRS）的相关性较强（r = -0.25，P<0.0001）。
MoCA在捕捉PSP认知衰退方面的敏感性似乎有限。
